Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis

While covalent Bruton's tyrosine kinase inhibitors (cBTKis) have become a standard of care treatment for relapsed/refractory mantle cell lymphoma (R/R MCL), response duration is limited and resistance to BTKi and/or adverse events develop in a subset of patients. However, little real-world evid...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lymphoma, myeloma and leukemia Vol. 24; no. 10; pp. e350 - e358.e1
Main Authors: Squires, Patrick, Puckett, Justin, Ryland, Katherine Elizabeth, Kamal-Bahl, Sachin, Raut, Monika, Doshi, Jalpa, Huntington, Scott F.
Format: Journal Article
Language:English
Published: United States Elsevier Inc 01-10-2024
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract While covalent Bruton's tyrosine kinase inhibitors (cBTKis) have become a standard of care treatment for relapsed/refractory mantle cell lymphoma (R/R MCL), response duration is limited and resistance to BTKi and/or adverse events develop in a subset of patients. However, little real-world evidence on post-cBTKi clinical and economic outcomes exists for these patients. This retrospective study used 2010 to 2019 U.S. Medicare claims, to identify elderly (≥ 66 years) patients with newly-diagnosed MCL who received third-line (3L) treatment and had evidence of cBTKi use in a prior line of therapy. Outcomes were assessed ≥ 12-months post 3L-treatment initiation and included treatment patterns, all-cause and MCL-related HRU and costs, and overall survival. The final sample contained 230 elderly patients with R/R MCL receiving 3L treatment who had cBTKi use in a prior line of therapy (mean age 75.0, 21.7% age > 80 years; 67.4% male; 93.9% White). Common 3L treatments included chemotherapy (26.1%), lenalidomide (18.7%), and bortezomib (18.3%); 1-quarter (25.7%) of patients received a cBTKi (17.8% ibrutinib; 7.8% acalabrutinib). Overall survival was poor from 3L treatment initiation (median OS = 9.4 months; 1-years survival rate = 43.7%). Patients exhibited high rates of HRU (73.6% experienced hospitalization) and substantial costs ($145,726) in the 12-months after 3L initiation. A large unmet need exists in this patient subpopulation, highlighting the importance of ongoing development of novel therapeutics. Treating older adults with relapsed mantle cell lymphoma (MCL) beyond Bruton tyrosine kinase inhibitors may be challenging. We conducted a real-world study of 3L + MCL therapy using 100% Medicare claims and found limited treatment options. Survival was poor and healthcare costs were high. These findings confirm a large unmet need and highlight the importance of ongoing development of novel therapeutics.
AbstractList While covalent Bruton's tyrosine kinase inhibitors (cBTKis) have become a standard of care treatment for relapsed/refractory mantle cell lymphoma (R/R MCL), response duration is limited and resistance to BTKi and/or adverse events develop in a subset of patients. However, little real-world evidence on post-cBTKi clinical and economic outcomes exists for these patients. This retrospective study used 2010 to 2019 U.S. Medicare claims, to identify elderly (≥ 66 years) patients with newly-diagnosed MCL who received third-line (3L) treatment and had evidence of cBTKi use in a prior line of therapy. Outcomes were assessed ≥ 12-months post 3L-treatment initiation and included treatment patterns, all-cause and MCL-related HRU and costs, and overall survival. The final sample contained 230 elderly patients with R/R MCL receiving 3L treatment who had cBTKi use in a prior line of therapy (mean age 75.0, 21.7% age > 80 years; 67.4% male; 93.9% White). Common 3L treatments included chemotherapy (26.1%), lenalidomide (18.7%), and bortezomib (18.3%); 1-quarter (25.7%) of patients received a cBTKi (17.8% ibrutinib; 7.8% acalabrutinib). Overall survival was poor from 3L treatment initiation (median OS = 9.4 months; 1-years survival rate = 43.7%). Patients exhibited high rates of HRU (73.6% experienced hospitalization) and substantial costs ($145,726) in the 12-months after 3L initiation. A large unmet need exists in this patient subpopulation, highlighting the importance of ongoing development of novel therapeutics.
While covalent Bruton's tyrosine kinase inhibitors (cBTKis) have become a standard of care treatment for relapsed/refractory mantle cell lymphoma (R/R MCL), response duration is limited and resistance to BTKi and/or adverse events develop in a subset of patients. However, little real-world evidence on post-cBTKi clinical and economic outcomes exists for these patients.BACKGROUNDWhile covalent Bruton's tyrosine kinase inhibitors (cBTKis) have become a standard of care treatment for relapsed/refractory mantle cell lymphoma (R/R MCL), response duration is limited and resistance to BTKi and/or adverse events develop in a subset of patients. However, little real-world evidence on post-cBTKi clinical and economic outcomes exists for these patients.This retrospective study used 2010 to 2019 U.S. Medicare claims, to identify elderly (≥ 66 years) patients with newly-diagnosed MCL who received third-line (3L) treatment and had evidence of cBTKi use in a prior line of therapy. Outcomes were assessed ≥ 12-months post 3L-treatment initiation and included treatment patterns, all-cause and MCL-related HRU and costs, and overall survival.PATIENTS AND METHODSThis retrospective study used 2010 to 2019 U.S. Medicare claims, to identify elderly (≥ 66 years) patients with newly-diagnosed MCL who received third-line (3L) treatment and had evidence of cBTKi use in a prior line of therapy. Outcomes were assessed ≥ 12-months post 3L-treatment initiation and included treatment patterns, all-cause and MCL-related HRU and costs, and overall survival.The final sample contained 230 elderly patients with R/R MCL receiving 3L treatment who had cBTKi use in a prior line of therapy (mean age 75.0, 21.7% age > 80 years; 67.4% male; 93.9% White). Common 3L treatments included chemotherapy (26.1%), lenalidomide (18.7%), and bortezomib (18.3%); 1-quarter (25.7%) of patients received a cBTKi (17.8% ibrutinib; 7.8% acalabrutinib). Overall survival was poor from 3L treatment initiation (median OS = 9.4 months; 1-years survival rate = 43.7%). Patients exhibited high rates of HRU (73.6% experienced hospitalization) and substantial costs ($145,726) in the 12-months after 3L initiation.RESULTSThe final sample contained 230 elderly patients with R/R MCL receiving 3L treatment who had cBTKi use in a prior line of therapy (mean age 75.0, 21.7% age > 80 years; 67.4% male; 93.9% White). Common 3L treatments included chemotherapy (26.1%), lenalidomide (18.7%), and bortezomib (18.3%); 1-quarter (25.7%) of patients received a cBTKi (17.8% ibrutinib; 7.8% acalabrutinib). Overall survival was poor from 3L treatment initiation (median OS = 9.4 months; 1-years survival rate = 43.7%). Patients exhibited high rates of HRU (73.6% experienced hospitalization) and substantial costs ($145,726) in the 12-months after 3L initiation.A large unmet need exists in this patient subpopulation, highlighting the importance of ongoing development of novel therapeutics.CONCLUSIONA large unmet need exists in this patient subpopulation, highlighting the importance of ongoing development of novel therapeutics.
While covalent Bruton's tyrosine kinase inhibitors (cBTKis) have become a standard of care treatment for relapsed/refractory mantle cell lymphoma (R/R MCL), response duration is limited and resistance to BTKi and/or adverse events develop in a subset of patients. However, little real-world evidence on post-cBTKi clinical and economic outcomes exists for these patients. This retrospective study used 2010 to 2019 U.S. Medicare claims, to identify elderly (≥ 66 years) patients with newly-diagnosed MCL who received third-line (3L) treatment and had evidence of cBTKi use in a prior line of therapy. Outcomes were assessed ≥ 12-months post 3L-treatment initiation and included treatment patterns, all-cause and MCL-related HRU and costs, and overall survival. The final sample contained 230 elderly patients with R/R MCL receiving 3L treatment who had cBTKi use in a prior line of therapy (mean age 75.0, 21.7% age > 80 years; 67.4% male; 93.9% White). Common 3L treatments included chemotherapy (26.1%), lenalidomide (18.7%), and bortezomib (18.3%); 1-quarter (25.7%) of patients received a cBTKi (17.8% ibrutinib; 7.8% acalabrutinib). Overall survival was poor from 3L treatment initiation (median OS = 9.4 months; 1-years survival rate = 43.7%). Patients exhibited high rates of HRU (73.6% experienced hospitalization) and substantial costs ($145,726) in the 12-months after 3L initiation. A large unmet need exists in this patient subpopulation, highlighting the importance of ongoing development of novel therapeutics. Treating older adults with relapsed mantle cell lymphoma (MCL) beyond Bruton tyrosine kinase inhibitors may be challenging. We conducted a real-world study of 3L + MCL therapy using 100% Medicare claims and found limited treatment options. Survival was poor and healthcare costs were high. These findings confirm a large unmet need and highlight the importance of ongoing development of novel therapeutics.
Author Kamal-Bahl, Sachin
Raut, Monika
Doshi, Jalpa
Huntington, Scott F.
Puckett, Justin
Ryland, Katherine Elizabeth
Squires, Patrick
Author_xml – sequence: 1
  givenname: Patrick
  surname: Squires
  fullname: Squires, Patrick
  organization: Merck & Co, Inc, Rahway, NJ
– sequence: 2
  givenname: Justin
  orcidid: 0000-0002-5135-7216
  surname: Puckett
  fullname: Puckett, Justin
  email: justin@coviahealthsolutions.com
  organization: COVIA Health Solutions, Lansdale, PA
– sequence: 3
  givenname: Katherine Elizabeth
  orcidid: 0009-0001-1749-7880
  surname: Ryland
  fullname: Ryland, Katherine Elizabeth
  organization: Merck & Co, Inc, Rahway, NJ
– sequence: 4
  givenname: Sachin
  surname: Kamal-Bahl
  fullname: Kamal-Bahl, Sachin
  email: sachin@coviahealthsolutions.com
  organization: COVIA Health Solutions, Lansdale, PA
– sequence: 5
  givenname: Monika
  surname: Raut
  fullname: Raut, Monika
  organization: Merck & Co, Inc, Rahway, NJ
– sequence: 6
  givenname: Jalpa
  surname: Doshi
  fullname: Doshi, Jalpa
  organization: Division of General Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
– sequence: 7
  givenname: Scott F.
  surname: Huntington
  fullname: Huntington, Scott F.
  organization: Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39034204$$D View this record in MEDLINE/PubMed
BookMark eNp9kE1v1DAQhi3Uin7AH-CAfOTQhLGdbDYSl3a1fIitqGBRj5ZjT8Arx27tJFL_fb1s6bEnj6z3fTTznJEjHzwS8o5ByYAtPu5K7QZXcuBVCXUJXLwip5zVvOCLRXv0PNdwQs5S2gE0AKx9TU5EC6LiUJ2S-ScqV9yG6AzdRlTjgH6kN2ocMfp0QX9NcbazchdUeUPXOvgwWE2vpmjQ08sh-D907QxG90CvV5t902ZCojcRZxumlP__cdHQWzv-pfpq-92mN-S4Vy7h26f3nPz-vN6uvhabH1--rS43heaiGYuOCYMtArRC9IhYMawVE7oxS64XrarVEuuuY7zSgA1wBU2LnTL9kve9Mkackw8H7l0M9xOmUQ42aXROeczLSQFLkS01Lc9RfojqGFKK2Mu7aAcVHyQDufctd3LvW-59S6hl9p1L75_4Uzegea78F5wDnw4BzFfOFqNMOgvSaGxEPUoT7Ev8RwgulFE
Cites_doi 10.1111/bjh.15567
10.1111/bjh.16922
10.1016/j.jgo.2020.12.013
10.1002/ajh.26109
10.1111/bjh.18519
10.1016/S0140-6736(15)00667-4
10.1097/PPO.0000000000000412
10.2147/OTT.S155778
10.1080/10428194.2021.1919662
10.1182/blood-2015-03-635326
10.2147/BLCTT.S426588
10.6004/jnccn.2021.0054
10.1016/j.clinthera.2021.06.012
10.1007/s11912-022-01272-6
10.1200/JCO.2008.19.6121
10.1002/cam4.2565
10.1016/S0140-6736(21)00224-5
10.1158/1078-0432.CCR-19-3703
10.1002/ajh.26306
10.1056/NEJMoa1200920
10.1186/s13045-016-0313-y
10.1182/bloodadvances.2022007247
10.1056/NEJMoa1306220
10.1002/cncr.23608
10.1080/10428194.2023.2234525
10.21873/anticanres.14846
10.1002/cam4.2268
10.1038/s41375-019-0575-9
10.3390/jpm11080764
10.1016/j.jacep.2018.06.004
10.3390/cancers12051328
10.1080/10428194.2018.1509320
10.1182/blood.2019852368
ContentType Journal Article
Copyright 2024
Copyright © 2024. Published by Elsevier Inc.
Copyright_xml – notice: 2024
– notice: Copyright © 2024. Published by Elsevier Inc.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1016/j.clml.2024.05.023
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2152-2669
EndPage e358.e1
ExternalDocumentID 10_1016_j_clml_2024_05_023
39034204
S215226502400226X
Genre Journal Article
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
1P~
1~.
4.4
457
4G.
53G
5VS
6PF
7-5
8P~
AACTN
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQQT
AAWTL
AAXKI
AAXUO
ABBQC
ABMAC
ABMZM
ABXDB
ACDAQ
ACGFS
ACRLP
ADBBV
ADEZE
ADMUD
AEBSH
AEKER
AENEX
AEVXI
AFCTW
AFJKZ
AFKWA
AFRHN
AFTJW
AFXIZ
AGHFR
AGUBO
AGYEJ
AIEXJ
AIKHN
AITUG
AJOXV
AJRQY
AJUYK
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
AXJTR
BKOJK
BLXMC
BNPGV
C45
CAG
COF
DU5
EBS
EFJIC
EJD
EMB
EMOBN
F5P
FDB
FEDTE
FIRID
FNPLU
FYGXN
GBLVA
HVGLF
HZ~
KOM
M41
MET
MO0
O-L
O9-
OAUVE
OC~
OO-
OVD
P-8
P-9
PC.
Q38
ROL
SDF
SEL
SES
SPCBC
SSH
SSZ
SV3
T5K
TEORI
XH2
Z5R
~G-
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c237t-b13de9e00933feee41e5a13c7d82c69a5a8e5bb124c0e702a079ebadf82ffadd3
ISSN 2152-2650
2152-2669
IngestDate Sat Oct 26 03:55:06 EDT 2024
Wed Oct 30 12:35:32 EDT 2024
Sat Nov 02 12:22:48 EDT 2024
Sat Oct 26 15:42:11 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords Costs
Unmet need
Medicare
Ibrutinib
Mantle cell lymphoma
Language English
License Copyright © 2024. Published by Elsevier Inc.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c237t-b13de9e00933feee41e5a13c7d82c69a5a8e5bb124c0e702a079ebadf82ffadd3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0009-0001-1749-7880
0000-0002-5135-7216
PMID 39034204
PQID 3083215792
PQPubID 23479
ParticipantIDs proquest_miscellaneous_3083215792
crossref_primary_10_1016_j_clml_2024_05_023
pubmed_primary_39034204
elsevier_sciencedirect_doi_10_1016_j_clml_2024_05_023
PublicationCentury 2000
PublicationDate October 2024
2024-Oct
2024-10-00
20241001
PublicationDateYYYYMMDD 2024-10-01
PublicationDate_xml – month: 10
  year: 2024
  text: October 2024
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Clinical lymphoma, myeloma and leukemia
PublicationTitleAlternate Clin Lymphoma Myeloma Leuk
PublicationYear 2024
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Squires, Puckett, Ryland (bib0030) 2023; 64
Zhou, Wang, Fang (bib0002) 2008; 113
Alsuhebany, Pan, Holovac, Do, McBride (bib0017) 2023; 13
Wang, Blum, Martin (bib0013) 2015; 126
Karmali, Switchenko, Goyal (bib0005) 2021; 96
Martin, Chadburn, Christos (bib0006) 2009; 27
Mato, Shah, Jurczak (bib0023) 2021; 397
Dreyling, Jurczak, Jerkeman (bib0008) 2016; 387
Ganatra, Sharma, Shah (bib0012) 2018; 4
Jain, Kanagal-Shamanna, Zhang (bib0034) 2021; 96
Shouse, Danilov, Artz (bib0021) 2022; 24
Weaver, Peng, Ji, Gilbertson, Pease, Morrison (bib0028) 2021; 12
Song, Zhou, Zou (bib0009) 2020; 26
Wang, Rule, Zinzani (bib0018) 2019; 33
Burger (bib0015) 2019; 25
Jeon, Yoon, Min (bib0019) 2019; 8
Mantle Cell Lymphoma. Lymphoma Research Foundation. Accessed November 28, 2022.
Narkhede, Goyal, Shea, Mehta, Giri (bib0033) 2022; 6
Wang, Rule, Martin (bib0007) 2013; 369
Girard, Reneau, Devata (bib0011) 2019; 12
Sharman, Kabadi, Clark, Andorsky (bib0004) 2021; 192
Goyal, Jain, Nagar (bib0029) 2021; 62
Witzig, Inwards (bib0010) 2019; 133
SAS: Analytics, Artificial intelligence and data management | SAS. Accessed November 30, 2022.
Jain, Kanagal-Shamanna, Zhang (bib0020) 2018; 183
Kluin-Nelemans, Hoster, Hermine (bib0003) 2012; 367
Ghosh, Emond, Lafeuille, Côté-Sergent, Lefebvre, Huang (bib0025) 2021; 43
Goyal, Nagar, Kabadi, Kaye, Seal, Mato (bib0026) 2019; 60
Kabadi, Goyal, Nagar, Kaye, Davis (bib0024) 2019; 8
Kabadi, Byfield, Le, Olufade (bib0027) 2021; 41
George, Mullick Chowdhury, Hart (bib0016) 2020; 12
Zelenetz, Gordon, Chang (bib0031) 2021; 19
Hess, Dreyling, Oberic (bib0035) 2023; 202
Wu, Liu, Tsui, Liu (bib0014) 2016; 9
Lewis, Cheah (bib0022) 2021; 11
Karmali (10.1016/j.clml.2024.05.023_bib0005) 2021; 96
Goyal (10.1016/j.clml.2024.05.023_bib0026) 2019; 60
Squires (10.1016/j.clml.2024.05.023_bib0030) 2023; 64
Zhou (10.1016/j.clml.2024.05.023_bib0002) 2008; 113
Dreyling (10.1016/j.clml.2024.05.023_bib0008) 2016; 387
George (10.1016/j.clml.2024.05.023_bib0016) 2020; 12
Sharman (10.1016/j.clml.2024.05.023_bib0004) 2021; 192
Wang (10.1016/j.clml.2024.05.023_bib0018) 2019; 33
Jeon (10.1016/j.clml.2024.05.023_bib0019) 2019; 8
Jain (10.1016/j.clml.2024.05.023_bib0034) 2021; 96
10.1016/j.clml.2024.05.023_bib0032
Kabadi (10.1016/j.clml.2024.05.023_bib0024) 2019; 8
Witzig (10.1016/j.clml.2024.05.023_bib0010) 2019; 133
Burger (10.1016/j.clml.2024.05.023_bib0015) 2019; 25
Wang (10.1016/j.clml.2024.05.023_bib0007) 2013; 369
Jain (10.1016/j.clml.2024.05.023_bib0020) 2018; 183
Lewis (10.1016/j.clml.2024.05.023_bib0022) 2021; 11
Shouse (10.1016/j.clml.2024.05.023_bib0021) 2022; 24
Martin (10.1016/j.clml.2024.05.023_bib0006) 2009; 27
Mato (10.1016/j.clml.2024.05.023_bib0023) 2021; 397
Goyal (10.1016/j.clml.2024.05.023_bib0029) 2021; 62
Girard (10.1016/j.clml.2024.05.023_bib0011) 2019; 12
Weaver (10.1016/j.clml.2024.05.023_bib0028) 2021; 12
Kluin-Nelemans (10.1016/j.clml.2024.05.023_bib0003) 2012; 367
Wu (10.1016/j.clml.2024.05.023_bib0014) 2016; 9
Alsuhebany (10.1016/j.clml.2024.05.023_bib0017) 2023; 13
10.1016/j.clml.2024.05.023_bib0001
Zelenetz (10.1016/j.clml.2024.05.023_bib0031) 2021; 19
Kabadi (10.1016/j.clml.2024.05.023_bib0027) 2021; 41
Ghosh (10.1016/j.clml.2024.05.023_bib0025) 2021; 43
Wang (10.1016/j.clml.2024.05.023_bib0013) 2015; 126
Song (10.1016/j.clml.2024.05.023_bib0009) 2020; 26
Narkhede (10.1016/j.clml.2024.05.023_bib0033) 2022; 6
Hess (10.1016/j.clml.2024.05.023_bib0035) 2023; 202
Ganatra (10.1016/j.clml.2024.05.023_bib0012) 2018; 4
References_xml – volume: 8
  start-page: 6860
  year: 2019
  end-page: 6870
  ident: bib0019
  article-title: Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience
  publication-title: Cancer Med
  contributor:
    fullname: Min
– volume: 41
  start-page: 927
  year: 2021
  end-page: 936
  ident: bib0027
  article-title: Adverse events and economic burden among patients receiving systemic treatment for mantle cell lymphoma: a real-world retrospective cohort study
  publication-title: Anticancer Res
  contributor:
    fullname: Olufade
– volume: 62
  start-page: 1325
  year: 2021
  end-page: 1334
  ident: bib0029
  article-title: Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma
  publication-title: Leuk Lymphoma
  contributor:
    fullname: Nagar
– volume: 12
  start-page: 1328
  year: 2020
  ident: bib0016
  article-title: Ibrutinib resistance mechanisms and treatment strategies for B-cell lymphomas
  publication-title: Cancers
  contributor:
    fullname: Hart
– volume: 397
  start-page: 892
  year: 2021
  end-page: 901
  ident: bib0023
  article-title: Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
  publication-title: Lancet Lond Engl
  contributor:
    fullname: Jurczak
– volume: 183
  start-page: 578
  year: 2018
  end-page: 587
  ident: bib0020
  article-title: Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib
  publication-title: Br J Haematol
  contributor:
    fullname: Zhang
– volume: 202
  start-page: 749
  year: 2023
  end-page: 759
  ident: bib0035
  article-title: Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR-2 retrospective chart review study
  publication-title: Br J Haematol
  contributor:
    fullname: Oberic
– volume: 24
  start-page: 1189
  year: 2022
  end-page: 1199
  ident: bib0021
  article-title: CAR T-cell therapy in the older person: indications and risks
  publication-title: Curr Oncol Rep
  contributor:
    fullname: Artz
– volume: 96
  start-page: E137
  year: 2021
  end-page: E140
  ident: bib0034
  article-title: Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib
  publication-title: Am J Hematol
  contributor:
    fullname: Zhang
– volume: 387
  start-page: 770
  year: 2016
  end-page: 778
  ident: bib0008
  article-title: Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
  publication-title: Lancet Lond Engl
  contributor:
    fullname: Jerkeman
– volume: 33
  start-page: 2762
  year: 2019
  end-page: 2766
  ident: bib0018
  article-title: Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
  publication-title: Leukemia
  contributor:
    fullname: Zinzani
– volume: 133
  start-page: 2570
  year: 2019
  end-page: 2574
  ident: bib0010
  article-title: Acalabrutinib for mantle cell lymphoma
  publication-title: Blood
  contributor:
    fullname: Inwards
– volume: 6
  start-page: 4122
  year: 2022
  end-page: 4131
  ident: bib0033
  article-title: Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma
  publication-title: Blood Adv
  contributor:
    fullname: Giri
– volume: 43
  start-page: 1285
  year: 2021
  end-page: 1299
  ident: bib0025
  article-title: Treatment patterns among patients with mantle cell lymphoma and comparison of healthcare resource utilization and costs among relapsed/refractory patients treated with ibrutinib or chemoimmunotherapy: a real-world retrospective study
  publication-title: Clin Ther
  contributor:
    fullname: Huang
– volume: 19
  start-page: 1218
  year: 2021
  end-page: 1230
  ident: bib0031
  article-title: NCCN guidelines® insights: B-cell lymphomas, version 5.2021
  publication-title: J Natl Compr Cancer Netw JNCCN
  contributor:
    fullname: Chang
– volume: 367
  start-page: 520
  year: 2012
  end-page: 531
  ident: bib0003
  article-title: Treatment of older patients with mantle-cell lymphoma
  publication-title: N Engl J Med
  contributor:
    fullname: Hermine
– volume: 4
  start-page: 1491
  year: 2018
  end-page: 1500
  ident: bib0012
  article-title: Ibrutinib-associated atrial fibrillation
  publication-title: JACC Clin Electrophysiol
  contributor:
    fullname: Shah
– volume: 25
  start-page: 386
  year: 2019
  end-page: 393
  ident: bib0015
  article-title: BTK inhibitors: present and future
  publication-title: Cancer J Sudbury Mass
  contributor:
    fullname: Burger
– volume: 13
  start-page: 67
  year: 2023
  end-page: 76
  ident: bib0017
  article-title: Zanubrutinib in mantle cell lymphoma management: a comprehensive review
  publication-title: Blood Lymphat Cancer Targets Ther
  contributor:
    fullname: McBride
– volume: 96
  start-page: 1374
  year: 2021
  end-page: 1384
  ident: bib0005
  article-title: Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era
  publication-title: Am J Hematol
  contributor:
    fullname: Goyal
– volume: 64
  start-page: 1752
  year: 2023
  end-page: 1770
  ident: bib0030
  article-title: Assessing unmet need among elderly medicare beneficiaries with mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs
  publication-title: Leuk Lymphoma
  contributor:
    fullname: Ryland
– volume: 369
  start-page: 507
  year: 2013
  end-page: 516
  ident: bib0007
  article-title: Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
  publication-title: N Engl J Med
  contributor:
    fullname: Martin
– volume: 9
  start-page: 80
  year: 2016
  ident: bib0014
  article-title: Second-generation inhibitors of Bruton tyrosine kinase
  publication-title: J Hematol OncolJ Hematol Oncol
  contributor:
    fullname: Liu
– volume: 12
  start-page: 894
  year: 2021
  end-page: 901
  ident: bib0028
  article-title: A medicare database analysis of practice patterns in patients with mantle cell lymphoma
  publication-title: J Geriatr Oncol
  contributor:
    fullname: Morrison
– volume: 26
  start-page: 4216
  year: 2020
  end-page: 4224
  ident: bib0009
  article-title: Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton's tyrosine kinase
  publication-title: Clin Cancer Res Off J Am Assoc Cancer Res
  contributor:
    fullname: Zou
– volume: 113
  start-page: 791
  year: 2008
  end-page: 798
  ident: bib0002
  article-title: Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004
  publication-title: Cancer
  contributor:
    fullname: Fang
– volume: 192
  start-page: 737
  year: 2021
  end-page: 746
  ident: bib0004
  article-title: Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study
  publication-title: Br J Haematol
  contributor:
    fullname: Andorsky
– volume: 126
  start-page: 739
  year: 2015
  end-page: 745
  ident: bib0013
  article-title: Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
  publication-title: Blood
  contributor:
    fullname: Martin
– volume: 8
  start-page: 3803
  year: 2019
  end-page: 3810
  ident: bib0024
  article-title: Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States
  publication-title: Cancer Med
  contributor:
    fullname: Davis
– volume: 12
  start-page: 8003
  year: 2019
  end-page: 8014
  ident: bib0011
  article-title: Evaluating acalabrutinib in the treatment of mantle cell lymphoma: design, development, and place in therapy
  publication-title: OncoTargets Ther
  contributor:
    fullname: Devata
– volume: 11
  start-page: 764
  year: 2021
  ident: bib0022
  article-title: Non-covalent BTK inhibitors—the new BTKids on the block for B-cell malignancies
  publication-title: J Pers Med
  contributor:
    fullname: Cheah
– volume: 27
  start-page: 1209
  year: 2009
  end-page: 1213
  ident: bib0006
  article-title: Outcome of deferred initial therapy in mantle-cell lymphoma
  publication-title: J Clin Oncol Off J Am Soc Clin Oncol
  contributor:
    fullname: Christos
– volume: 60
  start-page: 955
  year: 2019
  end-page: 963
  ident: bib0026
  article-title: Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States
  publication-title: Leuk Lymphoma
  contributor:
    fullname: Mato
– volume: 183
  start-page: 578
  issue: 4
  year: 2018
  ident: 10.1016/j.clml.2024.05.023_bib0020
  article-title: Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib
  publication-title: Br J Haematol
  doi: 10.1111/bjh.15567
  contributor:
    fullname: Jain
– volume: 192
  start-page: 737
  issue: 4
  year: 2021
  ident: 10.1016/j.clml.2024.05.023_bib0004
  article-title: Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study
  publication-title: Br J Haematol
  doi: 10.1111/bjh.16922
  contributor:
    fullname: Sharman
– volume: 12
  start-page: 894
  issue: 6
  year: 2021
  ident: 10.1016/j.clml.2024.05.023_bib0028
  article-title: A medicare database analysis of practice patterns in patients with mantle cell lymphoma
  publication-title: J Geriatr Oncol
  doi: 10.1016/j.jgo.2020.12.013
  contributor:
    fullname: Weaver
– volume: 96
  start-page: E137
  issue: 5
  year: 2021
  ident: 10.1016/j.clml.2024.05.023_bib0034
  article-title: Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib
  publication-title: Am J Hematol
  doi: 10.1002/ajh.26109
  contributor:
    fullname: Jain
– volume: 202
  start-page: 749
  issue: 4
  year: 2023
  ident: 10.1016/j.clml.2024.05.023_bib0035
  article-title: Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR-2 retrospective chart review study
  publication-title: Br J Haematol
  doi: 10.1111/bjh.18519
  contributor:
    fullname: Hess
– volume: 387
  start-page: 770
  issue: 10020
  year: 2016
  ident: 10.1016/j.clml.2024.05.023_bib0008
  article-title: Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
  publication-title: Lancet Lond Engl
  doi: 10.1016/S0140-6736(15)00667-4
  contributor:
    fullname: Dreyling
– volume: 25
  start-page: 386
  issue: 6
  year: 2019
  ident: 10.1016/j.clml.2024.05.023_bib0015
  article-title: BTK inhibitors: present and future
  publication-title: Cancer J Sudbury Mass
  doi: 10.1097/PPO.0000000000000412
  contributor:
    fullname: Burger
– volume: 12
  start-page: 8003
  year: 2019
  ident: 10.1016/j.clml.2024.05.023_bib0011
  article-title: Evaluating acalabrutinib in the treatment of mantle cell lymphoma: design, development, and place in therapy
  publication-title: OncoTargets Ther
  doi: 10.2147/OTT.S155778
  contributor:
    fullname: Girard
– ident: 10.1016/j.clml.2024.05.023_bib0001
– volume: 62
  start-page: 1325
  issue: 6
  year: 2021
  ident: 10.1016/j.clml.2024.05.023_bib0029
  article-title: Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma
  publication-title: Leuk Lymphoma
  doi: 10.1080/10428194.2021.1919662
  contributor:
    fullname: Goyal
– volume: 126
  start-page: 739
  issue: 6
  year: 2015
  ident: 10.1016/j.clml.2024.05.023_bib0013
  article-title: Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
  publication-title: Blood
  doi: 10.1182/blood-2015-03-635326
  contributor:
    fullname: Wang
– volume: 13
  start-page: 67
  year: 2023
  ident: 10.1016/j.clml.2024.05.023_bib0017
  article-title: Zanubrutinib in mantle cell lymphoma management: a comprehensive review
  publication-title: Blood Lymphat Cancer Targets Ther
  doi: 10.2147/BLCTT.S426588
  contributor:
    fullname: Alsuhebany
– volume: 19
  start-page: 1218
  issue: 11
  year: 2021
  ident: 10.1016/j.clml.2024.05.023_bib0031
  article-title: NCCN guidelines® insights: B-cell lymphomas, version 5.2021
  publication-title: J Natl Compr Cancer Netw JNCCN
  doi: 10.6004/jnccn.2021.0054
  contributor:
    fullname: Zelenetz
– volume: 43
  start-page: 1285
  issue: 8
  year: 2021
  ident: 10.1016/j.clml.2024.05.023_bib0025
  article-title: Treatment patterns among patients with mantle cell lymphoma and comparison of healthcare resource utilization and costs among relapsed/refractory patients treated with ibrutinib or chemoimmunotherapy: a real-world retrospective study
  publication-title: Clin Ther
  doi: 10.1016/j.clinthera.2021.06.012
  contributor:
    fullname: Ghosh
– volume: 24
  start-page: 1189
  issue: 9
  year: 2022
  ident: 10.1016/j.clml.2024.05.023_bib0021
  article-title: CAR T-cell therapy in the older person: indications and risks
  publication-title: Curr Oncol Rep
  doi: 10.1007/s11912-022-01272-6
  contributor:
    fullname: Shouse
– ident: 10.1016/j.clml.2024.05.023_bib0032
– volume: 27
  start-page: 1209
  issue: 8
  year: 2009
  ident: 10.1016/j.clml.2024.05.023_bib0006
  article-title: Outcome of deferred initial therapy in mantle-cell lymphoma
  publication-title: J Clin Oncol Off J Am Soc Clin Oncol
  doi: 10.1200/JCO.2008.19.6121
  contributor:
    fullname: Martin
– volume: 8
  start-page: 6860
  issue: 16
  year: 2019
  ident: 10.1016/j.clml.2024.05.023_bib0019
  article-title: Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience
  publication-title: Cancer Med
  doi: 10.1002/cam4.2565
  contributor:
    fullname: Jeon
– volume: 397
  start-page: 892
  issue: 10277
  year: 2021
  ident: 10.1016/j.clml.2024.05.023_bib0023
  article-title: Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
  publication-title: Lancet Lond Engl
  doi: 10.1016/S0140-6736(21)00224-5
  contributor:
    fullname: Mato
– volume: 26
  start-page: 4216
  issue: 16
  year: 2020
  ident: 10.1016/j.clml.2024.05.023_bib0009
  article-title: Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton's tyrosine kinase
  publication-title: Clin Cancer Res Off J Am Assoc Cancer Res
  doi: 10.1158/1078-0432.CCR-19-3703
  contributor:
    fullname: Song
– volume: 96
  start-page: 1374
  issue: 11
  year: 2021
  ident: 10.1016/j.clml.2024.05.023_bib0005
  article-title: Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era
  publication-title: Am J Hematol
  doi: 10.1002/ajh.26306
  contributor:
    fullname: Karmali
– volume: 367
  start-page: 520
  issue: 6
  year: 2012
  ident: 10.1016/j.clml.2024.05.023_bib0003
  article-title: Treatment of older patients with mantle-cell lymphoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1200920
  contributor:
    fullname: Kluin-Nelemans
– volume: 9
  start-page: 80
  issue: 1
  year: 2016
  ident: 10.1016/j.clml.2024.05.023_bib0014
  article-title: Second-generation inhibitors of Bruton tyrosine kinase
  publication-title: J Hematol OncolJ Hematol Oncol
  doi: 10.1186/s13045-016-0313-y
  contributor:
    fullname: Wu
– volume: 6
  start-page: 4122
  issue: 14
  year: 2022
  ident: 10.1016/j.clml.2024.05.023_bib0033
  article-title: Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2022007247
  contributor:
    fullname: Narkhede
– volume: 369
  start-page: 507
  issue: 6
  year: 2013
  ident: 10.1016/j.clml.2024.05.023_bib0007
  article-title: Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1306220
  contributor:
    fullname: Wang
– volume: 113
  start-page: 791
  issue: 4
  year: 2008
  ident: 10.1016/j.clml.2024.05.023_bib0002
  article-title: Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004
  publication-title: Cancer
  doi: 10.1002/cncr.23608
  contributor:
    fullname: Zhou
– volume: 64
  start-page: 1752
  issue: 11
  year: 2023
  ident: 10.1016/j.clml.2024.05.023_bib0030
  article-title: Assessing unmet need among elderly medicare beneficiaries with mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs
  publication-title: Leuk Lymphoma
  doi: 10.1080/10428194.2023.2234525
  contributor:
    fullname: Squires
– volume: 41
  start-page: 927
  issue: 2
  year: 2021
  ident: 10.1016/j.clml.2024.05.023_bib0027
  article-title: Adverse events and economic burden among patients receiving systemic treatment for mantle cell lymphoma: a real-world retrospective cohort study
  publication-title: Anticancer Res
  doi: 10.21873/anticanres.14846
  contributor:
    fullname: Kabadi
– volume: 8
  start-page: 3803
  issue: 8
  year: 2019
  ident: 10.1016/j.clml.2024.05.023_bib0024
  article-title: Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States
  publication-title: Cancer Med
  doi: 10.1002/cam4.2268
  contributor:
    fullname: Kabadi
– volume: 33
  start-page: 2762
  issue: 11
  year: 2019
  ident: 10.1016/j.clml.2024.05.023_bib0018
  article-title: Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
  publication-title: Leukemia
  doi: 10.1038/s41375-019-0575-9
  contributor:
    fullname: Wang
– volume: 11
  start-page: 764
  issue: 8
  year: 2021
  ident: 10.1016/j.clml.2024.05.023_bib0022
  article-title: Non-covalent BTK inhibitors—the new BTKids on the block for B-cell malignancies
  publication-title: J Pers Med
  doi: 10.3390/jpm11080764
  contributor:
    fullname: Lewis
– volume: 4
  start-page: 1491
  issue: 12
  year: 2018
  ident: 10.1016/j.clml.2024.05.023_bib0012
  article-title: Ibrutinib-associated atrial fibrillation
  publication-title: JACC Clin Electrophysiol
  doi: 10.1016/j.jacep.2018.06.004
  contributor:
    fullname: Ganatra
– volume: 12
  start-page: 1328
  issue: 5
  year: 2020
  ident: 10.1016/j.clml.2024.05.023_bib0016
  article-title: Ibrutinib resistance mechanisms and treatment strategies for B-cell lymphomas
  publication-title: Cancers
  doi: 10.3390/cancers12051328
  contributor:
    fullname: George
– volume: 60
  start-page: 955
  issue: 4
  year: 2019
  ident: 10.1016/j.clml.2024.05.023_bib0026
  article-title: Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States
  publication-title: Leuk Lymphoma
  doi: 10.1080/10428194.2018.1509320
  contributor:
    fullname: Goyal
– volume: 133
  start-page: 2570
  issue: 24
  year: 2019
  ident: 10.1016/j.clml.2024.05.023_bib0010
  article-title: Acalabrutinib for mantle cell lymphoma
  publication-title: Blood
  doi: 10.1182/blood.2019852368
  contributor:
    fullname: Witzig
SSID ssj0070019
Score 2.4054272
Snippet While covalent Bruton's tyrosine kinase inhibitors (cBTKis) have become a standard of care treatment for relapsed/refractory mantle cell lymphoma (R/R MCL),...
SourceID proquest
crossref
pubmed
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage e350
SubjectTerms Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors
Aged
Aged, 80 and over
Cost of Illness
Costs
Female
Humans
Ibrutinib
Lymphoma, Mantle-Cell - drug therapy
Lymphoma, Mantle-Cell - economics
Lymphoma, Mantle-Cell - mortality
Lymphoma, Mantle-Cell - therapy
Male
Mantle cell lymphoma
Medicare
Protein Kinase Inhibitors - economics
Protein Kinase Inhibitors - therapeutic use
Retrospective Studies
Unmet need
Title Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis
URI https://dx.doi.org/10.1016/j.clml.2024.05.023
https://www.ncbi.nlm.nih.gov/pubmed/39034204
https://www.proquest.com/docview/3083215792
Volume 24
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe6TUK8IL4pXzISb12mxE6W5LErQYMxNNEi-hY5yUV0JB1i66T-99z5I-kmhgCJl8i18mH5fj2fz7-7Y-y1qNNQqlR5URJLLyyCxEtSbKVVgCpZBSC0w-1wGn-cJ2-yMBsMXDWBvu-_Shr7UNYUOfsX0u5eih3YRpnjFaWO1z-S-ye0_DxLkelI5Cc6i6Yxmacr1A6XOs-_PjlwockjE9EwGuvyQxlV727Wo-PJB3p6oQPhKN8TcWaxX78bjdUvmrp-MDtanG_auRMXcNmsES5nrTZR2zU02NRfbWD1DdpFtyhMiZG8WTWgiyA6IeaHPcKi0mN96NrasTKPXBjjFZaaWUhUi_NxoL42xv9N1NFNT4cIO86cdb-5EJwrDFGqy-uJfZO91ql0E5btoOtvKGiQ9k5wP5M9CH65lhi3xule2bR0RiVCneLVREdfy9E9pVHQIIiRi435FtsRqPlQ8e6M32Xz9844oFN-2pF1o7ZxXIZyeP1LN9lKN-2FtE00u8vu2M0MHxsU3mMDWN5nt44tXeMBu-zByDswcgfGXe6guMtRkNwBkRsgcg1EboHIEYjcAZH3QOQWiJyAyA0QH7LPb7PZ5NCzhT68Usj4wisCWUEK2rtWA0AYQKQCWcZVIsr9VEUqgago0BQtfYh9ofw4hUJVdSLqGhdo-YhtL8-W8ITxNCanQCQLqMowUVVSxKoIy7KKS-KYyCEbuSnNv5t8LrkjOp7mJICcBJD7UY4CGLLIzXpuLVJjaeYIkt8-98qJKEd1TWdwagk4Lbn0qTRYFKdiyB4b2XXjkCnl4_TDp__41Wfsdv-3ec62L36s4AXbOq9WLy0MfwKjlMUY
link.rule.ids 315,782,786,27933,27934
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Real-World+Treatment+Patterns%2C+Survival%2C+and+Economic+Burden+Among+Elderly+MCL+Patients+Previously+Treated+With+cBTKis&rft.jtitle=Clinical+lymphoma%2C+myeloma+and+leukemia&rft.au=Squires%2C+Patrick&rft.au=Puckett%2C+Justin&rft.au=Ryland%2C+Katherine+Elizabeth&rft.au=Kamal-Bahl%2C+Sachin&rft.date=2024-10-01&rft.pub=Elsevier+Inc&rft.issn=2152-2650&rft.volume=24&rft.issue=10&rft.spage=e350&rft.epage=e358.e1&rft_id=info:doi/10.1016%2Fj.clml.2024.05.023&rft.externalDocID=S215226502400226X
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2152-2650&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2152-2650&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2152-2650&client=summon